Craig Landau

Dr. Landau entered the pharmaceutical industry in 1997, and two years later joined Purdue Pharma L.P. Through his 14 years with the U.S. organization, he would eventually become Purdue Pharma L.P.’s chief medical officer and VP of R&D Innovation, Clinical and Medical Affairs. In this role and as part of the company’s management team, he and the R&D organization he led were responsible for a number of successful health policy initiatives as well as product registrations in the United States and other regions, including Butrans, reformulated OxyContin, Targiniq ER, and Hysingla ER.

In 2013, Dr. Landau was appointed president and CEO of Purdue Pharma (Canada). Executives say over the last three years, Purdue Pharma (Canada) has become a more diversified and stable business through the completion of multiple strategic business development transactions, as well as through contributions from its internal R&D function. In addition to a portfolio of approved prescription products for the treatment of pain, Purdue Pharma (Canada) offers prescription treatment options for patients suffering from attention deficit hyperactivity disorder (ADHD), chemotherapy-induced nausea and vomiting (CINV) and ophthalmic conditions, as well as over-the-counter (OTC) laxative, decongestant and antiseptic products.

Landau earned his B.Sc. in physiology and anatomy from Cornell University and his M.D. from Mount Sinai School of Medicine. He completed his anesthesiology residency at Yale University, with specialty training in chronic pain management, obstetric and peripheral vascular anesthesia. He is also a U.S. Army Veteran, having concluded a distinguished 14-year career in 2005.